Showing 1801-1810 of 2314 results for "".
- Survey: 80% of Consumers Would Be More Likely To Visit a Doctor if They Could See the Exact Out-of-Pocket Cost On Their Smartphonehttps://modernod.com/news/survey-80-of-consumers-would-be-more-likely-to-visit-a-doctor-if-they-could-see-the-exact-out-of-pocket-cost-on-their-smartphone/2476190/Metova, a provider of mobile, connected car, connected home and IoT Solutions, announced findings from a “Mobile First” survey on health care and technology, revealing the sentiment of over 1,000 consumers who currently have health care. The survey was conducted to research the growin
- Staar Surgical Expects Fourth Quarter ICL Sales to Rise 42%; China Units Nearly Double, U.S. Market Returns to Growthhttps://modernod.com/news/staar-surgical-expects-fourth-quarter-icl-sales-to-rise-42-china-units-nearly-double-u-s-market-returns-to-growth/2476216/Staar Surgical, which provided preliminary sales results for the fourth quarter ending December 28, 2018, said it expects fourth quarter ICL net sales to increase approximately 42% over the prior year period. Total net sales for the fourth quarter are expected to be approximately $31.2 million an
- Study: Dietary Supplements Don’t Prevent Chronic Diseasehttps://modernod.com/news/study-dietary-supplements-dont-prevent-chronic-disease/2476158/As the US nutritional and dietary supplements market remains robust — an estimated $41.1 billion in sales in 2016 — the Academy of Nutrition and Dietetics is cautioning against the routine and indiscriminate use of these dietary add-ons, according to a Medscape
- Envision Research Institute Announces Search for Post Doctoral Fellows to Study Low Visionhttps://modernod.com/news/envision-research-institute-announces-search-for-post-doctoral-fellows-to-study-low-vision/2479664/The Gigi & Carl Allen Envision Research Institute (ERI) is now calling for letters of intent to apply for its next round of postdoctoral research fellowships. Launched in 2015 with a goal to restore function to those who are blind and visually impaired, the ERI provides access to funds, facil
- Clearside Biomedical’s Combination Therapy in RVO Does Not Meet Primary Endpoint in Phase 3 Trialhttps://modernod.com/news/clearside-biomedicals-combination-therapy-in-rvo-does-not-meet-its-primary-endpoint-in-phase-3-trial/2479701/Clearside Biomedical announced that the primary endpoint was not achieved in its phase 3 clinical trial (SAPPHIRE) investigating the superiority of XIPERE (formerly suprachoroidal CLS-TA) used together with the intravitreal anti-VEGF agent Eylea (aflibercept), compared to intravit
- Penn’s Experimental Gene Therapy Saves Night Vision in Dogs, Paving the Way for Human Testshttps://modernod.com/news/penns-experimental-gene-therapy-saves-night-vision-in-dogs-paving-the-way-for-human-tests/2479925/In 1990, scientists discovered a genetic mutation that turns an important light-sensing protein in the retina into a toxin that steadily destroys the ability to see in low light. <
- FDA Approves 12-Week Dosing for Eylea in Wet AMD Patientshttps://modernod.com/news/fda-approves-12-week-dosing-for-eylea-in-wet-amd-patients/2479932/Regeneron announced that the FDA has approved a supplemental Biologics License Application for Eylea (aflibercept) injection in patients with wet age-related macular degeneration (AMD). The application was based on second-year data from the phase 3 VIEW 1 and 2 trials in which patients with wet A
- Silicon Valley Eye Doctor Named Optometrist of the Year By American Optometric Associationhttps://modernod.com/news/silicon-valley-eye-doctor-named-optometrist-of-the-year-by-american-optometric-association/2480071/The California Optometric Association (COA) announced that David M. Redman, OD, has been named the “Optometrist of the Year” for 2017 by the American Optometric Association (AOA). Dr. Redman is a practicing optometrist and partner in Precision Eyecare Centers in San Jose and Mountain View. Dr. Re
- Ultrasonic Phaco Remains Dominant, but New Technologies Ready to Challengehttps://modernod.com/news/ultrasonic-phaco-remains-dominant-but-new-technologies-ready-to-challenge/2480114/Market Scope expects surgeons to perform nearly 18.5 million phaco procedures globally in 2018, and dedicated packs and accessories will make up more than 72 percent of the $1.6 billion in global cataract equipment revenues. Two factors will fuel modest growth in the cataract equipment mar
- Market Scope: Patient Demand for Better Vision Will Drive Double-Digit Growth in IOL Revenueshttps://modernod.com/news/patient-demand-for-better-vision-will-drive-double-digit-growth-in-iol-revenues/2480268/Technological innovations in premium IOLs will help drive global IOL revenues to more than $6.1 billion by 2023, according to Market Scope data.